News from the GP-TCM RA:

1. GP-TCM RA Calls for President-Elect and BoD Candidates

- With the approval of the current GP-TCM RA Board of Directors (BoD), the Secretariat is organising the 2nd GP-TCM RA election for nine BoD members, including President-Elect;
- Based on the Bylaws, Prof. Ian Sutherland of UK’s Brunel University, a member who does not run election himself has been approved by BoD to serve as Chairman of the election;
- The BoD being elected will succeed the current BoD from 1st Jan. 2015 to decide principles and future directions of the GP-TCM RA;
- Only members can be elected. If you want to run election but are not members yet, please apply membership now: http://www.gp-tcm.org/about/membership/
- Applicants for President-Elect and BoD membership positions need to submit independent applications;
- The new President-Elect will take office on 1st Jan. 2015, when current President-Elect Prof. De-an Guo becomes President and the current President Prof. Rudolf Bauer becomes Past President. The newly elected President-Elect will be member of the BoD and the Executive Council, and will become President of GP-TCM RA on 1st Jan. 2017;
- Details of candidates will be presented at the Association website and the names of the candidates will be sent to every member of the Association on 1 August;
- Election period: 1 September 2014 until 30 September 2014;
- Announcement of results in October 2014 GP-TCM RA Newsletter.
- What is required from candidates of BoD members, including President-Elect?
  - A recent photograph;
  - Which position applied for;
  - 200-word self-introduction in English;
  - 200-word personal statement: Why do you apply for the position? What will you do if elected?
- Please email the information requested above to membership@gp-tcm.org and secretary-general@gp-tcm.org, no later than 25 July 2014.

2. GP-TCM RA Appoints Three Honorary Members

Prof. Kaixian Chen, Prof. Gerhard Franz and Prof. Boli Zhang were unanimously agreed by Board of Directors of the GP-TCM RA as awardees of the prestigious GP-TCM RA Honorary Membership, in recognition of their outstanding contribution to TCM research. The decision was made at the 15th Teleconference of the BoD held on Friday 13th June 2014.

Thus, they joined Prof. Geoffrey Burnstock (University College London, UK), Prof. Yung-Chi Cheng (Yale University, USA), Prof. Brian Clark (University of Aarhus, Denmark), Prof. Jan van der Greef (TNO & Leiden University, The Netherlands) and Prof. Xinsheng Yao (Jinan University, China) as the 6th, 7th and 8th Honorary Members of the GP-TCM RA.

The GP-TCM RA Board of Directors sincerely congratulates Prof. Chen, Prof. Franz and Prof. Zhang for receiving such an exceptional honour and looks forward to working with all our Honorary Members closely in the development, refinement and dissemination of good practice in TCM research and in the efforts to make TCM safer and more effective so as to better serve the peoples from all around the world.
Prof. Kaixian CHEN (陈凯先，President of Shanghai University of Traditional Chinese Medicine, SHUTCM) is appointed Honorary Member of the GP-TCM RA. Prof. Chen is an academician of the Chinese Academy of Sciences and is Chairman of the Academic Committee of Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences. He graduated from Department of Chemistry, Fudan University, Shanghai, China, in 1967, and received a PhD in Medicinal Chemistry from SIMM in 1985. He worked as a visiting scholar in Prof. Bernard Pullman’s laboratory, Institute de Biologie Physico-chimique, Paris (1985-1988), and was awarded THE NINE CHOUCROWN PRIZE in Oct. 1986. In 1990, he became Professor of Medicinal Chemistry at SIMM and was finally appointed Director of SIMM (1996-2004). As a renowned medicinal chemist, Prof. Chen has pioneered multidisciplinary research of innovative Chinese Materia Medica, promoted modernisation and internationalisation of traditional Chinese medicine, and is a leader in designing national and municipal policies on biomedicine and innovative pharmaceuticals.

http://sourcedb.cas.cn/sourcedb_simm_cas/yw/zjrcyw/201112/t20111212_3411155.html
http://www.shutcm.edu.cn/web/guest/ckx

Prof. Gerhard FRANZ (University of Regensburg, Germany) is appointed Honorary Member of the GP-TCM RA. Prof. Dr. Gerhard Franz obtained his Diploma as Pharmacist from the University of Karlsruhe/Germany (1963) and his doctoral degree as a fellow of the Deutscher Akademischer Austauschdienst (DAAD) at the University of Fribourg/ Switzerland (1966). He carried out research at the Department of Biochemistry at the University of California/Berkeley. He was appointed as Professor at the University of Regensburg, Department of Pharmaceutical Sciences in 1977. He was guest Professor at the University of Basel/Switzerland, the University of Grenoble/ France and the University of Harbin (China). He is a former President of the Society of Medicinal Plant Research (GA). Prof. Franz is the author of more than 260 scientific papers and several books. His research was recognised by the EGON STAHL AWARD (1985), the KNEIPP-AWARD (1994), the HERMANN-THOMS AWARD of the DPhG (2003) and Honorary Membership of GA (2006). He is corresponding member of the Belgian Medical Association and the 'Académie Nationale de Pharmacie' (France). He obtained the Silver Medal of the 'Académie Nationale de Pharmacie' as an acknowledgement for his long activity for the European Pharmacopoeia in 2014. Prof. Franz was editor and co-editor of several scientific journals. He was appointed as Chairman of the Group of Experts 13B and of the TCM Working Party of the European Pharmacopoeia Commission Strasbourg (France) and as Chairman for the Phytochemistry Group of the German Pharmacopoeia (DAB) and the German Pharmacopoeia Commission at the BfArM in Bonn.

Prof. Boli ZHANG (张伯礼，President, China Academy of Chinese Medical Science and President of Tianjin University of TCM, China) is appointed Honorary Member of the GP-TCM RA. Prof. Zhang is an academician of Chinese Academy of Engineering, Vice Chairman of Chinese Association of the Integration of Traditional and Western Medicine (CAIM), deputy commissioner of Department of Incretion of Chinese Association of Chinese Medicine (CACM), deputy commissioner of the medical branch of Chinese Association of Higher Education (CAHE), president of Educational Instruction Committee (EIC) of World Federation of Chinese Medicine Societies (WFCMS), and the director of the key laboratory for TCM Prescription of the
Ministry of Education. Prof. Zhang is Visiting or Honorary Professor of Russian Academy of Medical Sciences, Nankai University, Health Science Center of Peking University, China Pharmaceutical University, Guangzhou University of Chinese Medicine, etc. Prof. Zhang is engaged in basic research of cardiovascular and cerebrovascular diseases and Traditional Chinese Medicine. Conducting the study of vascular dementia (VD), he established the grouping criteria of VD and treatment scheme according to stable, fluctuating and aggravating phases. The effective rate of Yi-shen Hua-zhuo in treating VD 360 patients was up to 39.3%. He invented the study method of cerebrospinal fluid pharmacology, revealed the mechanisms of protective effects of TCM on nerve cells, and won the Second Prize for the National Development of Science and Technology. Through great amount of samples of clinical epidemiological survey, firstly identified the developing rule of syndrome and premonition of stroke, and started the comparing study for general treatment of stroke in acute stage and formulated individualization of combined therapy plan, and won the First Prize for the Development of Science and Technology awarded by the Ministry of Education. Prof. Zhang has held two successive “973” projects, Basic Research of Key Problem in Prescription Science and Basic Research of Prescription Compatibility, established the leading new pattern and optimum designing of modern TCM prescription with constituent compatibility, and won the Second Prize for the National Development of Science and Technology. His team has won 5 Prizes for the National Development of Science and Technology, and over 20 First or Second Prizes of Provincial Development of Science and Technology. Prof. Zhang has trained over one hundred doctoral or master students, published more than 120 papers and 16 patents.

http://news13.tjutcm.edu.cn/info/1536/3004.htm
http://www.catcm.ac.cn/publicfiles/business/htmlfiles/zgzy/xrld/list.html

3. GP-TCM RA Appoints Four Interest Group Co-Chairs
The GP-TCM RA Board of Directors would like to extend our warmest congratulations!

Dr Fan QU 曲凡 is appointed Co-Chair of the Pharmacology and Toxicology Interest Group, which is chaired by BoD member Prof. Pierre Duez (University of Mons, Belgium). Dr QU is an Associate Professor and PhD Supervisor at Women’s Hospital/School of Medicine, Zhejiang University, China. His research fields include pharmacology and toxicology of herbal medicine, complementary and alternative medicine as well as reproductive endocrinology. As PI, he has been awarded more than 10 grants in the last five years, including from National Natural Science Foundation of China (NNSFC) and the “Twelfth Five-Year” National Science and Technology Programme of China. As first or corresponding author, he has published over 40 peer-reviewed papers and has filed 10 patents. He was awarded the second rank of National Scientific and Technological Prize of China (2011), Outstanding Young Investigator of Western Medicine and TCM (2012), Academic Award of Natural Science of Zhejiang Province (2012). Dr QU was a WP10 member in the FP7 GP-TCM project and is a reviewer of NNSFC and China’s Postdoctoral Science Foundation.

Prof. Jianping LIU 刘建平 is appointed Co-Chair of Acupuncture Interest Group, which is chaired by BoD member Prof. Nicola Robinson (London Southbank University, UK). Jianping Liu, MD, PhD, is the Founding Director of Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine (BUCM) since May 2005. He is PhD supervisor, Head of BUCM School of Basic Medical Science, an advisor for Traditional Medicine of WHO-WPRO (West Pacific Region Office), and a “Chang Jiang Scholar” Professor awarded by the Ministry of Education, P.R. China. He completed his PhD in infectious disease in 1992, and has background in clinical
medicine, traditional Chinese medicine, public health, clinical epidemiology, and Cochrane Collaboration activities. His main research interests are in the areas of systematic review of interventions of traditional Chinese medicine, clinical research and research methodology. He is the member of the Cochrane Complementary Medicine Field Advisory Board, member of the Board of Directors of International Society of Complementary Medicine Research (ISCMR); editors of the Cochrane Hepato-Biliary Group, “European Journal of Integrative Medicine”, “FACT”, Associate Editors of BMC Complementary and Alternative Medicine, “Chinese Medicine” journal, and Complementary Therapy in Medicine, World Journal of Traditional Chinese Medicine, Journal of Traditional Chinese Medical Science; editors of “Chinese Journal of Epidemiology”, “Chinese Journal of Integrated Traditional and Western Medicine”, “Journal of Integrated Medicine” and “Journal of Evidence-Based Medicine”. He is a peer reviewer for more than 30 international journals. He authored 8 books, co-authored 8 books, and published more than 440 papers in peer reviewed journals. Dr Liu was a WP6 member in the FP7 GP-TCM project.

Prof. Yuan Shiun CHANG 張永勳 is appointed Co-Chair of the Quality Control Interest Group of the GP-TCM RA, which is chaired by BoD member Prof. Kelvin Chan (The University of Sydney and The University of West Sydney). Dr Chang is a Professor of Pharmacognosy at the Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, College of Pharmacy, China Medical University, Taichung, Taiwan. He received his Ph.D. degree in Pharmacognosy from University of Illinois at Chicago, Illinois, U.S.A. in 1989 under the supervision of late Professor Norman R. Farnsworth. Besides teaching, Professor Chang had served as Head of Herbal Pharmacy of China Medical University Hospital for more than 10 years. He collaborates closely with TCM communities in Taiwan, and organized various workshops and symposia for TCM practitioners. He had served as member of Committee of Chinese Medicine and Pharmacy, Department of Health, Taiwan for many years. Professor Chang also engage in the quality control studies of TCM herbs. He had just help Department of Health, Taiwan compiled the second edition of Taiwan Herbal Pharmacopeia (THP) with 300 items and published “Color Illustration of Taiwan Herbal Pharmacopeia” in 2013. Professor Chang has also been invited since 2011 to join Hong Kong Chinese Materia Medica Standard Project as a PI from China Medical University. Professor Chang had just been appointed as GP-TCM RA QCIG Co-chair. To date, he has published 150 scientific papers and 20 books in TCM fields.

Prof. Wei-Dong ZHANG 张卫东 is appointed Co-Chair of the Regulatory Affairs Interest Group, which is chaired by BoD member Dr Tai-Ping Fan (University of Cambridge, UK). Sitting on committees of the Chinese Pharmacopoeia and the China Food and Drug Administration, Prof. Weidong Zhang is the Chief Director of Modern Research Center for Traditional Chinese Medicine (MRCTCM) of Second Military Medical University, Shanghai, China, the Vice President of the Specialty Committee of Chinese Medicine Chemistry, the World Federation of Chinese Medicine Societies and Professor of Chang Jiang Scholars Programme (Ministry of Education, China). He earned his Ph.D. from Shanghai Institute of Pharmaceutical Industry in 1998 and then worked at Paul Sabatier University of France as a visiting scientist in 1998-2000. Prof. Zhang’s major achievements were made in the field of bioactive natural products discovery from TCM, QA&QC of herbal medicine, metabolomics and chemical biology of natural products. Prof. Zhang won an award from the National Outstanding Young Scientist Foundation of China in 2007 and was an awardee of the Qiushi Outstanding Youth Award in 2008. By now Prof. Zhang has published more than 400 peer-reviewed papers in international academic journals, including JACS, Chemical

4. Warmest welcome to 5 new Corporate Members!

We are delighted to announce that we now have a total of 22 Corporate Members. The 5 new institutions are Agilent Technologies (China), Co. Ltd., Beijing University of Chinese Medicine, Beijing Institute of Radiation Medicine, Guangzhou University of TCM and Macau University of Science & Technology. More details on these new members will be featured in the next edition of the Newsletter.

Reports of recent activities of BoD Members

1. At the 8th Inauguration of Endowed Professorships, the University of Hong Kong (HKU) conferred the Vivian Taam Wong Professor in Integrative Medicine on Prof. Lixing Lao 劉力行, Director of the School of Chinese Medicine, HKU. Prior to joining HKU, he was a full professor in the Department of Family and Community Medicine and the Director of TCM Research Program in the Center for Integrative Medicine, School of Medicine, University of Maryland, Baltimore, USA.

Professor Lao conducts translational research that bridges basic science, clinical trials, and “real world” acupuncture clinical practice with funding from the National Institutes of Health and the US Department of Defense. Widely recognized for his contributions to acupuncture / TCM research methodology, Professor Lao served as a co-president of the Society for Acupuncture Research from 2003-2007 and was elected Vice President of the World Federation of Acupuncture and Moxibustion Societies and Secretary General of the Consortium for Globalization of Chinese Medicine.

Professor Vivian Taam Wong JP, a GP-TCM RA BoD member and the Chief Executive of Modernized Chinese Medicine International Association, commented: "Hong Kong is in a unique position to study the practice of Traditional Chinese Medicine in its pure form because it is illegal for Chinese medicine practitioners to use Western diagnostic and treatment modalities. However, integrating Chinese and Western medicine is practised by most individuals in the community. HKU, with our wide spectrum of world class experts in different scientific fields, offers fertile research ground for this Professor who would strive to combine the best of both systems to formulate the new medicine of the 21st century, as directed by our former Minister of Health, Professor Chen Zhu."

http://www.youtube.com/watch?v=4-PaEoNfL94
2. PhD fellowships in Hong Kong: GP-TCM RA BoD member Prof. Aiping LU, Dean and Chair Professor in Chinese Medicine, School of Chinese Medicine, Hong Kong Baptist University, is seeking PhD students to participate in his Translational Medical Research & Innovative Drug Development’ Program under ‘Hong Kong PhD Fellowship Scheme’ (HKPF), with a focus on molecular mechanism involved in diseases related to, but not limited to musculoskeletal system, and therapeutic intervention by natural products and herbal medicine. One particular interest is to develop design strategy of combinatory drug and combination therapy using both knowledge-based approach (e.g. data mining, systems biology, network pharmacology) and structure-based approach (e.g. computational chemistry and computer-aided drug design). The other is to develop next-generation smart drugs (e.g. target moiety linked to a therapeutic natural product by aptamer-based modification strategy. The HKPF will provide an annual stipend of HK$240,000 (approximately US$30,000) and a conference and research-related travel allowance of HK$10,000 (approximately US$1,300) per year up to three years. The PhD students will receive research training in ‘Institute for Advancing Translational Medicine in Bone & Joint Diseases’ (TMBJ, http://tmbj.hkbu.edu.hk/) in Hong Kong Baptist University (HKBU, http://buwww.hkbu.edu.hk/eng/main/index.jsp), which is supervised by ‘School of Chinese Medicine’ (SCM, http://scm.hkbu.edu.hk/en/home/index.php) in HKBU. The academic members in TMBJ, including Prof. Aiping Lu and Dr. Ge Zhang, will supervise the Ph.D. students. Please refer to their CVs and research projects in TMBJ homepage.

The requirements of our program under the HKPF will be, but not limited to, the following:

• High motivation and enthusiasm with a keen interest in interdisciplinary research and with an excellent degree (Master or Diploma) in pharmacology, biology, chemistry, pharmacognosy, pharmaceutics, bioinformatics, computational life science, biomedical engineering, mathematics, or health related areas.
• A few years of experience in the related disciplines. He/she should have proven records of success in the field of study.
• Excellent written and verbal communication skills to work with a multidisciplinary research team.

Please send your CV and a cover letter that specifically addresses the above requirements, before Oct 30, 2014, to Prof. Aiping LU: aipinglu@hkbu.edu.hk

4. **Meeting in Hong Kong:** GP-TCM RA BoD members Prof. Kelvin Chan and Prof. Rudolf Bauer attended the 8th International Advisory Board Meeting of Hong Kong Chinese Materia Medica Standards at Mira Hotel in Hong Kong from 17th – 20th June 2014, chaired by Dr. Constance CHAN, Director of Health, Hong Kong, China. They discussed the proposed content of Phase VII from HKCMMSO with 33 new monographs. Details can be found at [http://www.cmd.gov.hk/html/eng/service/hkcmms/cmmlist.html](http://www.cmd.gov.hk/html/eng/service/hkcmms/cmmlist.html)

5. **GP-TCM RA President visits Hong Kong University:** On 21st June, Prof. Rudolf Bauer visited Hong Kong Polytechnic University, Shenzhen Campus, met Dr. Daniel Mok and other colleagues, and promoted GP-TCM RA.
Meeting reports

The 15th GP-TCM RA BoD Teleconference was held at 10:00-12:00 BST (11:00-13:00 CEST; 17:00-19:00 Beijing Time; 19:00-21:00 Sydney Time), Friday 13th June 2014. The meeting was attended by Rudolf Bauer (Chair), De-an Guo, Tai-Ping Fan, Pierre Duez, Nicky Robinson, Monique Simmonds, Vivian Wong, Qihe Xu (Minutes); apologies were received from Kelvin Chan, Peter Hylands, Aiping Lu and Rob Verpoorte. The meeting approved the minutes of the 14th BoD teleconference and received reports from President, Vice-Presidents and Secretary-General. Prof. Kaixian CHEN, Gerhard FRANZ and Prof. Boli ZHANG were unanimously approved as Honorary Members. Dr. Fan Qu, Prof. Jianping Liu, Prof. Yuan Shiun Chang and Prof. Wei-Dong Zhang were appointed as GP-TCM RA Interest Group Co-Chairs. Membership development and elections were updated and it was agreed that bylaws amendments on some figures related to election were necessary and should be circulated to Members for approval. Time of the 4th Annual General Meeting and some details of the coming Annual Conference in Nanjing (Abstract assessment panel, Student Award Assessment Panel, poster and exhibition, etc) were discussed. The 4th GP-TCM RA BoD Face-to-Face Meeting will be held on the 18th July in Nanjing, China.

The 2nd Stakeholders Workshop of the EU's Science, Technology and Innovation Performance of China Project was held on 12th June 2014 in Brussels. Informed by Prof. Rudolf Bauer and Prof. Pierre Duez, GP-TCM RA Student Members Amandine Nachtergael and Valérian Bunel attended this meeting and provided the following meeting report:

The Workshop took place from 13:30 until 17:30 and presented the STI China project achievements. The STI China project was launched in January 2013 and will end in August 2014. The primary objective of the project is to assess the performances and evolution of the Science, Technology and Innovation (STI) sector in China and to analyze its economic impact on Chinese productivity and competitiveness, as well as on the global market. The insight gained should help inform and develop STI strategies for the EU, concerning China as a competitor as well as a partner.

The partners involved in the project are the Sociedade Portuguesa de Inovação SPI (www.spieurope.eu), The United Nations University - Maastricht Economic Research Institute on Innovation and Technology UNU-MERIT (www.merit.unu.edu) and the Austrian Institute of Technology AIT (www.ait.ac.at). Furthermore, two renowned Chinese universities have been contracted for local support: the Tsinghua University, Research Centre for Technological Innovation (www.innovation.tsinghua.edu.cn) and the Renmin University of China, School of Statistics (http://stat.ruc.edu.cn).

The work has been separated in specific objectives in the form of work packages:

- WP1: Identify, assess and update the data and indicators relevant to STI in China
- WP2: Provide a mapping of China’s research and innovation capabilities in selected technologies as well as their translation into the development of its industry
- WP3: Provide a description and an assessment of China’s efforts and policies to develop its STI capabilities, including its international strategy
- WP4: Provide a description and an assessment of framework conditions for innovation, in particular an overview of China’s innovation system
- WP5: Identify opportunities and challenges brought by the STI development of China

You will find, at the end of this report, links to the slides that were presented during the workshop. They detail the most relevant project results and achievements obtained within the 5 WPs. The first 2 WPs have been achieved through a collection of STI indicators and bibliometrics data. WP3 and WP4 methodology was based on a survey of Chinese and European STI stakeholders (WP3), desk research (WP4) and 101 interviews focusing on key foreign and Chinese stakeholders in China. WP5 depicts challenges and opportunities and establishes recommendations on thematic
areas of common interest, on higher education and research establishments, and on industrial stakeholders.

**Opportunities for international collaborations?** The project reveals that there is an increase in funding opportunities for China-EU collaboration – e.g. International Incoming/outgoing fellowships (H2020), new EU-CHINA Research and Innovation Partnership (ECRIP), Young Scientists fund (NSFC) and MoST call for proposals for EU-China Science and technology cooperative projects (call is currently open).

STI China project could become a valuable partner of GP-TCM RA. In identifying R&D opportunities in academic and industrial sectors of China, it could help in the creation of new collaborations in a sino-european context. These should particularly be of interest to individuals/organizations dealing with projects up to the prototypic/proof-of-concept step and requiring further development or industrialization.


**Future meetings:**

1. **Updates on the 3rd Annual Meeting of GP-TCM RA & 5th Annual Meeting of TCM Analysis Specialty Committee of WFCMS (18-20 July, 2014; Nanjing)**
   - The whole day of July 18 will be dedicated to GP-TCM RA activities and workshop on scientific writing by journal editors: Interest Group Sessions in the morning and afternoon, covering Quality Control, Pharmacology & Toxicology, Clinical Studies, Regulatory Affairs, Acupuncture; BoD Face-to-Face Meeting at lunchtime break; and Annual General Meeting in early evening (5.10pm-6.10pm).
   - All GP-TCM RA members are entitled to a 20% discount of their registration fees

2. **The Annual Meeting of the American Society of Pharmacognosy.** The Annual ASP meeting will be held from August 2nd - 6th, 2014 in Oxford, Mississippi, USA.
   - Prof. Rudolf Bauer will give a lecture on “Herbal medicinal products in Europe: Experience in development and regulation”.

3. **The 13th Meeting of Consortium for Globalization of Chinese Medicine (CGCM) will be held in Beijing on 27-29 August, 2014.**

   The Meeting is organized by China Academy of Chinese Medical Sciences. It provides a platform for regulatory-industrial-academic exchanges and potential research collaborations on various frontiers of Traditional Chinese Medicine among our worldwide CGCM members and guests. You are cordially invited to submit abstracts to share your exciting studies with us, also encouraged to forward this message to your colleagues and friends. The abstract submission form has been attached for your information. For more details of the meeting, please refer to the 13th CGCM Meeting website: [http://13th_cgcm.icmm.ac.cn/](http://13th_cgcm.icmm.ac.cn/).
Deadline for abstract submission: 30 June, 2014 (Monday)

Abstract submission for poster presentations of the Meeting is now open for all CGCM members and invited guests. Please submit your abstracts together with the attached Abstract Submission Form to centraloffice@tcmedicine.org on or before the deadline. Highlights of the posters would be discussed during the relevant discussion sessions. Conclusions, action plans and milestones are expected to be drawn.

To support postgraduates to attend the 13th CGCM Meeting, up to 50 Travel Grants are now open for application. Awardees will receive travel grant, free accommodation (shared room) and waiver of registration fee. You may wish to encourage your postgraduates to submit abstracts and apply for the Travel Grant.

Should you have any enquiries, please feel free to contact centraloffice@tcmedicine.org.

4. The Society for Medicinal Plant and Natural Product Research (GA) 62nd Annual Meeting will be held from 31st August to 4th September 2014 in Guimares, Portugal. http://ga2014.bio.uminho.pt/

The Congress will be held at the University of Minho, campus of Azurém, which is located in close vicinity to the medieval city centre of Guimarães, a UNESCO World Heritage Site. The historical city of Guimarães is located in Northern Portugal. The dynamic and colorful Minho Region is famous for its landscape and vineyards where the unique “Vinho Verde” wine is produced. The University of Minho is a leading university in Portugal and offers an excellent setting for the Congress. Plenary lectures by leading scientists, and several workshops will provide insights into various aspects of medicinal plant and natural product research.

5. The 11th World Congress of Chinese Medicine will be held in St. Petersburg, Russia on 1st-2nd October, 2014. You are warmly welcome to attend.

Key information about the Congress:

- **Organizer:** World Federation of Chinese Medicine Societies
- **Host:** Li’West Company of Russia
- **Theme:** Integrating Eastern and Western Culture, Exploring New Medical Model for Future
- **The Timetable:**
  - Registration on 30th September, 2014.
  - Attend the Congress on 1st-2nd October 2014.
- **About the Registration fee:** As the Council Member, the registration fee for you is the lowest: 670USD/Person (without Remittance Charge), and the registration fee does not include accommodation and flight ticket. Please remit either in USD or in EUR. **Please note:** When you transfer fees to us, please write down ‘your name + Russia Congress’ in the remarks, so that we can check your money easily then. After you transfer fees to us, please scan the remittance receipt (picture) and email it to wccm@vip.163.com.
Mons stories:

Ball P. *Information technology: Forgotten prophet of the Internet. Nature* 2014; 509: 425. After the 3rd Annual Meeting in Nanjing, the next GP-TCM RA Annual Meeting will be held in Mons, Belgium. This Nature article tells an almost forgotten story about the city: Mons houses the collections of the Mundaneum; that was conceived in the beginning of 20th century as a universal repository for all printed documents, i.e. a repository of universal knowledge. It is now considered as the first-ever example of what the Internet would become (“paper internet”; “Google ancestor”, etc). Collections have been mistreated for decades but are now valorized in a Mons museum that is being entirely renewed for 2015.

Yes, after Nanjing, let’s meet again in 2015 in Mons!

http://www.readcube.com/articles/10.1038/509425a?utm_campaign=readcube_access&utm_source=nature.com&utm_medium=purchase_option&utm_content=thumb_version

15th June 2014 was the Mons annual religious procession and fair. To get an idea of the ambiance, you may watch the following video:

https://www.youtube.com/watch?v=eLFu1sr-_TQ#t=14

This particular music is heard throughout the town!

Recommended readings:

1. Consultation: Possible Priorities for the 2016-17 Health, Demographic Change and Wellbeing Work Programme:

http://ec.europa.eu/eusurvey/runner/RTDpriorities_ICTforAHA_H2020SC1

2. On 16th June 2014, EMA published “Uptake of the traditional use registration scheme and implementation of the provisions of Directive 2004/24/EC in the EU Member States. Status: 31 December 2013”


3. Wu WY, et al. TCM-based new drug discovery and development in China. *Chin J Nat Med.* 2014;12:241-50. Over the past 30 years, China has significantly improved the drug development environment by establishing a series of policies for the regulation of new drug approval. The regulatory system for new drug evaluation and registration in China was gradually developed in accordance with international standards. The approval and registration of TCM in China became as strict as those of chemical drugs and biological products. In this review, TCM-based new drug discovery and development are introduced according to the TCM classification of nine categories.


**BACKGROUND:** There is a need for more Comparative Effectiveness Research (CER) on Chinese medicine (CM) to inform clinical and policy decision-making. This document aims to provide consensus advice for the design of CER trials on CM for researchers. It broadly aims to ensure more adequate design and optimal use of resources in generating evidence for CM to inform stakeholder decision-making.

**METHODS:** The Effectiveness Guidance Document (EGD) development was based on multiple consensus procedures (survey, written Delphi rounds, interactive consensus workshop, international expert review). To balance aspects of internal and external validity, multiple
stakeholders, including patients, clinicians, researchers and payers were involved in creating this document.

RESULTS: Recommendations were developed for "using available data" and "future clinical studies". The recommendations for future trials focus on randomized trials and cover the following areas: designing CER studies, treatments, expertise and setting, outcomes, study design and statistical analyses, economic evaluation, and publication.

CONCLUSION: The present EGD provides the first systematic methodological guidance for future CER trials on CM and can be applied to single or multi-component treatments. While CONSORT statements provide guidelines for reporting studies, EGDs provide recommendations for the design of future studies and can contribute to a more strategic use of limited research resources, as well as greater consistency in trial design.

5. 300 years on: The Resurrection of the Longitude Committee

6. The grand challenge of suicide in modern society: Is there a place for traditional medicine?
http://www.nature.com/news/suicide-watch-1.14691

7. Good practice in GM mouse studies
http://www.nature.com/news/misleading-mouse-studies-waste-medical-resources-1.14938
http://www.nature.com/news/preclinical-research-make-mouse-studies-work-1.14913
http://www.mousephenotype.org/goals-and-background


Human proteome mapped: Compiling mass spectrometry profiles of human tissues and cell lines, two separate groups publish near-complete drafts of the human proteome, The Scientist reports (By Anna Azvolinsky | May 28, 2014).
http://www.the-scientist.com/?articles.view/articleNo/40083/title/Human-Proteome-Mapped/

9. European Medicines Agency set to publish clinical-trial reports

11. The US Pharmacopoeia has developed a new Compendium for Herbal Ingredients:

The new Herbal Medicines Compendium (HMC) offers freely available testing standards to help ensure the quality of herbal ingredients used in traditional medicines: first set of standards in USP’s HMC proposed for public review and comment from parties around the globe.

http://click.icptrack.com/icp/relay.php?r=25410761&msgid=2197583&act=GYNT&c=141701&destination=http%3A%2F%2Fus.vocuspr.com%2FViewAttachment.aspx%3FEID%3DFA%252bPNYrFTXbseg4tQkoKiMVWV2FL05i3WJBb67nRGY%253d%26fd%3D1

First Ingredients Proposed for Public Input:

With the launch of HMC, USP is proposing the first 23 monographs for comment. These are:

- Phyllanthus amarus Aerial Parts
- Phyllanthus amarus Aerial Parts Powder
- Phyllanthus amarus Aerial Parts Powdered Extract
- Rhodiola rosea Root and Rhizome
- Rhodiola rosea Root and Rhizome Powder
- Rhodiola rosea Root and Rhizome Powdered Extract
- Rhodiola rosea Root and Rhizome Tincture
- Salvia miltiorrhiza Root and Rhizome
- Salvia miltiorrhiza Root and Rhizome Powder
- Salvia miltiorrhiza Root and Rhizome Powdered Extract
- Ganoderma lucidum Fruiting Body
- Ganoderma lucidum Fruiting Body Powder
- Ganoderma lucidum Fruiting Body Powdered Extract
- Lagerstroemia speciosa Leaf
- Lagerstroemia speciosa Leaf Powder
- Lagerstroemia speciosa Leaf Powdered Extract
- Trigonella foenum-graecum Seed
- Trigonella foenum-graecum Seed Powder
- Trigonella foenum-graecum Seed Powdered Extract
- Trigonella foenum-graecum Seed 4-Hydroxyisoleucine Powdered Extract
- Panax pseudoginseng Root and Rhizome
- Panax pseudoginseng Root and Rhizome Powder
- Panax pseudoginseng Root and Rhizome Powdered Extract

12. Nature China: Nature China highlights the best research coming out of Mainland China and Hong Kong, providing scientists from around the world with a convenient portal into publications drawn from across all scientific disciplines. Each week, Nature China editors select the best published research and provide a summary of the results. By organizing this research into a comprehensive, regularly updated, one-stop web portal, Nature China hope to help you quickly reach the resources you need to study, and to keep you up-to-date with the most significant research coming out of Mainland China and Hong Kong. http://www.natureasia.com/en/nchina/

13. China open access: The Chinese Academy of Sciences and the National Natural Science Foundation of China both announced new open-access policies on 16 May. All researchers and graduate students who are supported by the agencies are now required to make their publicly funded studies free to read. Research papers must be made accessible in online repositories no later than a year after their publication in an academic journal. See go.nature.com/ojrmfy for more. http://www.nature.com/news/chinese-agencies-announce-open-access-policies-1.15255

14. The European Journal of Integrative Medicine (www.elsevier.com/eujim) is pleased to alert that the following published articles with specific relevance to TCM are available as Open Access papers. The abstracts for the GP-TCM RA Nanjing meeting will be available together with
issue 6 of the journal later this year

- Ian Appleyard, et al. Should systematic reviews assess the risk of bias from sham–placebo acupuncture control procedures? http://dx.doi.org/10.1016/j.eujim.2014.03.004

- Shanshan Sun, et al. The association between TCM syndromes and SCAP polymorphisms in subjects with non-alcoholic fatty liver disease. http://dx.doi.org/10.1016/j.eujim.2013.06.003

- Lorna Ng, et al. Effectiveness of incorporating Tai Chi in a pulmonary rehabilitation program for Chronic Obstructive Pulmonary Disease (COPD) in primary care—A pilot randomized controlled trial. http://dx.doi.org/10.1016/j.eujim.2014.01.007


Acknowledgements
Contributions from Prof. Rudolf Bauer (Graz), Mr. Valérian Bunel (Brussels), Prof. Yuan Shiun Chang (TaiChung), Prof. Pierre Duez (Mons), Dr. Tai-Ping Fan (Cambridge), Prof. De-an Guo (Shanghai), Prof. Jianping Liu (Beijing), Prof. Aiping Lu (Hong Kong), Miss Amandine Nachtergael (Mons), Dr. Fan Qu (Hangzhou), Prof. Nicola Robinson (London), Prof. Vivian Wong (Hong Kong) and Dr. Qihe Xu (London), Prof. Wei-Dong Zhang (Shanghai) are gratefully acknowledged.